Galapagos increases share capital through subscription right exercises
March 20 2023 - 4:01PM
Galapagos increases share capital through subscription right
exercises
Mechelen, Belgium; 20
March
2023,
21.01
CET; regulated information –
Galapagos NV (Euronext & NASDAQ: GLPG) announces a
share capital increase arising from subscription right
exercises.
Galapagos issued 61,560 new ordinary shares on
20 March 2023, for a total capital increase (including issuance
premium) of EUR 1,769,850.00.
In accordance with Belgian transparency
legislation1, Galapagos also wishes to note that its total share
capital currently amounts to EUR 356,444,938.61, the total number
of securities conferring voting rights amounts to 65,897,071, which
is also the total number of voting rights (the denominator), and
all securities conferring voting rights and all voting rights are
of the same category. The total number of rights (formerly known as
‘warrants’) to subscribe to not yet issued securities conferring
voting rights is (i) 10,731,149 subscription rights under several
outstanding personnel subscription right plans, which equals
10,731,149 voting rights that may result from the exercise of those
subscription rights, and (ii) 1 subscription right issued to Gilead
Therapeutics to subscribe for a maximum number of shares that is
sufficient to bring the shareholding of Gilead (and its affiliated
companies) to 29.9% of the actually issued and outstanding shares
after the exercise of such subscription right. Galapagos does not
have any convertible bonds or shares without voting rights
outstanding.
About
GalapagosGalapagos is a fully integrated biotechnology
company focused on discovering, developing, and commercializing
innovative medicines. We are committed to improving patients’ lives
worldwide by targeting diseases with high unmet needs. Our R&D
capabilities cover multiple drug modalities, including small
molecules and cell therapies. Our portfolio comprises discovery
through to commercialized programs in immunology, oncology, and
other indications. Our first medicine for rheumatoid arthritis and
ulcerative colitis is available in Europe and Japan. For additional
information, please visit www.glpg.com or follow us
on LinkedIn or Twitter.
Contacts
Media
relations |
Investor
relations |
Marieke
Vermeersch |
Sofie Van
Gijsel |
+32 479
490 603 |
+1 781 296
1143 |
|
|
Elisa
Chenailler |
Sandra
Cauwenberghs |
+41 79 853 33
54 |
+32 495 58 46
63 |
|
ir@glpg.com |
Hélène de
Kruijs |
|
+31 6
22463921 |
|
media@glpg.com |
|
Forward-looking statements
This release may contain forward-looking
statements. Such forward-looking statements are not guarantees of
future results. These forward-looking statements speak only as of
the date of publication of this document. Galapagos expressly
disclaims any obligation to update any forward-looking statements
in this document, unless specifically required by law or
regulation.
1 Belgian Act of 2 May 2007 on the disclosure of
major shareholdings in issuers whose shares are admitted to trading
on a regulated market (as amended from time to time).
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2024 to Aug 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Aug 2023 to Aug 2024